Latest News and Press Releases
Want to stay updated on the latest news?
-
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
-
iTeos Therapeutics to Present at UBS Global Healthcare Conference Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel...
-
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
-
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
-
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and...
-
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
-
Gosselies, Belgium - March 5, 2019 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of...
-
iTeos Therapeutics to Participate in Upcoming Conferences in November Gosselies, Belgium – November 7, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...
-
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
-
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer...